Literature DB >> 18349465

High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment.

J Hofstra1, S Loves, B van Wageningen, J Ruinemans-Koerts, I Jansen, H de Boer.   

Abstract

BACKGROUND: Obesity can be associated with biochemical evidence of isolated hypogonadotropic hypogonadism (IHH) in men. Prevalence and severity of IHH in obese men are not exactly known.
OBJECTIVE: To assess the prevalence of IHH in obese men. DESIGN AND
SUBJECTS: Cross-sectional study of 160 obese men, BMI >30 kg/m2, who applied for medical or surgical treatment of obesity in a general teaching hospital. MAIN OUTCOME MEASURES: Total and calculated free testosterone (TT and FT) in relation to body mass index (BMI).
RESULTS: Mean age of the study population was 43.3 +/- 0.8 years (mean +/- SEM), BMI ranged from 30.0 to 65.7 kg/m2. TT and FT levels were inversely related to BMI (-0.48, p<0.0001). Total testosterone was subnormal in 57.5% and free testosterone in 35.6% of the subjects. The group of men with IHH was more obese, had higher Hba IC levels and had a 2.6 higher risk for cardiovascular disease. Decreased libido and erectile dysfunction were 7.1 and 6.7 times as common in IHH than in eugonadal obese men.
CONCLUSION: Reduced T levels, well into the hypogonadal range, are common in male obesity. Assessment of its clinical implications, and a search for the best mode of treatment are warranted.

Entities:  

Mesh:

Year:  2008        PMID: 18349465

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  33 in total

Review 1.  Metabolic regulation is important for spermatogenesis.

Authors:  Luís Rato; Marco G Alves; Sílvia Socorro; Ana I Duarte; José E Cavaco; Pedro F Oliveira
Journal:  Nat Rev Urol       Date:  2012-05-01       Impact factor: 14.432

2.  Prevalence of Hypogonadism in Low-Risk Prostate Cancer Survivors.

Authors:  Lily Agrawal; Rod Marianne Arceo-Mendoza; Adrienne Barnosky; Larissa Bresler; Maguy Chiha; Abigail Silva; Cory Wilczynski
Journal:  Fed Pract       Date:  2016-05

3.  The influence of age on bioavailable and free testosterone is independent of body mass index and glucose levels.

Authors:  Graziele Halmenschlager; Ernani Luis Rhoden; Charles Edison Riedner
Journal:  World J Urol       Date:  2011-07-08       Impact factor: 4.226

Review 4.  The silent spermatozoon: are man-made endocrine disruptors killing male fertility?

Authors:  Bradley D Anawalt
Journal:  Asian J Androl       Date:  2013-01-21       Impact factor: 3.285

Review 5.  Approach to male infertility and induction of spermatogenesis.

Authors:  Bradley D Anawalt
Journal:  J Clin Endocrinol Metab       Date:  2013-09       Impact factor: 5.958

6.  Testosterone concentrations in young pubertal and post-pubertal obese males.

Authors:  Muniza Mogri; Sandeep Dhindsa; Teresa Quattrin; Husam Ghanim; Paresh Dandona
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

7.  Testosterone and insulin resistance in the metabolic syndrome and T2DM in men.

Authors:  Preethi M Rao; Daniel M Kelly; T Hugh Jones
Journal:  Nat Rev Endocrinol       Date:  2013-06-25       Impact factor: 43.330

8.  Long-term follow-up of gonadal dysfunction in morbidly obese adolescent boys after bariatric surgery.

Authors:  Vivian L Chin; Kristen M Willliams; Tegan Donnelley; Marisa Censani; Rushika Conroy; Shulamit Lerner; Sharon E Oberfield; Donald J McMahon; Jeffrey Zitsman; Ilene Fennoy
Journal:  J Pediatr Endocrinol Metab       Date:  2018-11-27       Impact factor: 1.634

9.  Testosterone concentrations in diabetic and nondiabetic obese men.

Authors:  Sandeep Dhindsa; Michael G Miller; Cecilia L McWhirter; Donald E Mager; Husam Ghanim; Ajay Chaudhuri; Paresh Dandona
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

Review 10.  The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease.

Authors:  Abdulmaged M Traish; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.